Differentiation of Pancreatic Ductal Adenocarcinoma from Chronic Pancreatitis
Overview
This study evaluates the diagnostic performance of serum biomarkers GDF15, SYCN, and TSP-2 in differentiating pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) and healthy controls. GDF15 and SYCN showed significant elevation in PDAC.
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with increasing incidence and low survival rates. Accurate differentiation of PDAC from chronic pancreatitis (CP) is clinically challenging due to overlapping symptoms and imaging findings. Current biomarkers like CA19-9 have limitations.
Data Highlights
Biomarker
PDAC vs HCs AUC
PDAC vs CP AUC
Sensitivity
Specificity
GDF15
0.86
0.73
97%
71%
SYCN
0.77
0.65
-
94%
TSP-2
-
0.52
-
-
Combined GDF15 + SYCN
0.89
-
-
-
Key Findings
GDF15 and SYCN levels were significantly elevated in PDAC compared to CP and healthy controls.
GDF15 demonstrated the highest discrimination ability for PDAC vs healthy controls (AUC = 0.86).
SYCN showed high specificity (94%) but lower overall discrimination (AUC = 0.77).
TSP-2 showed no significant difference in levels between PDAC and CP (AUC = 0.52).
Clinical Implications
GDF15 and SYCN may serve as serum biomarkers for differentiating PDAC from chronic pancreatitis and healthy controls.
Conclusion
GDF15 and SYCN show potential as biomarkers for PDAC, while TSP-2 appears to have limited diagnostic value.
